Health Canada has authorised Seegene’s Allplex SARS CoV-2 FluA/FluB/RSV Assay under its Interim Order.
The new multiplex real-time PCR assay is designed to identify the N, S and RdRP genes, which are used to detect SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV), in a single test.
It enables the differentiation and amplification of respiratory symptoms simultaneously.
The Allplex SARS-CoV-2/Flu A/Flu B/RSV Assay can be run on the company’s integrated all-in-one automated platform, which enables high-throughput testing.
On 13 January, the company delivered 340,000 Covid-19 test kits to Canada to support the increasing demand for kits in the country.
Seegene chief sales and marketing officer Ho Yi said: “Demand for Covid-19 tests is skyrocketing due to the resurgence of confirmed cases.
“We are fully prepared to supply enough test kits globally and will continue to be strong global partners in the effort to manage the spread of Covid-19.”
The company also stated that the latest approval will allow it to increase awareness of its product in countries close to Canada, such as those in Latin America.
In a separate development, Seegene has delivered more than five million Covid-19 test kits to Israel to support detection of the Omicron variant and reduce its spread.
Last December, the company delivered nearly 1.7 million Covid-19 test kits along with associated consumables. An additional 3.4 million tests are planned to be delivered this month.
Seegene will send various products to Israel, including its Allplex SARS CoV-2 FluA/FluB/RSV Assay and Allplex SARS-CoV-2 Master Assay.
Last month, the company confirmed that its Allplex SARS-CoV-2 Master Assay has the ability to detect the new Omicron Covid-19 variant.